Odetiglucan

Odetiglucan
Odetiglucan

Clinical Development of Odetiglucan

----------

In a Phase 2 clinical trial, odetiglucan in combination with pembrolizumab was generally well-tolerated and demonstrated encouraging median overall survival (mOS), and disease control rates (DCR) in patients with chemotherapy-refractory, immune checkpoint inhibitor naïve metastatic triple-negative breast cancer (mTNBC) with a second arm evaluating advanced melanoma patients. We are building on these clinical data via our Phase 2 study of odetiglucan in combination with pembrolizumab in adult metastatic -breast cancer (mBC) patients who have failed hormone therapy +/- CDK4/6 inhibitors.

Clinically, we are initiating an additional Phase 1b study of odetiglucan in combination with an agonistic CD40 antibody (CD40a) in pancreatic ductal adenocarcinoma (PDAC).

Odetiglucan has also demonstrated increased response rates and disease control rates in patients with liver metastasis across varied tumor histologies, with multiple therapeutic classes. We plan to initiate a clinical trial further exploring this mechanism in early 2023.

The Odetiglucan Immune Complex

Odetiglucan, our immune modulator therapeutic candidate, has been observed to modulate both the innate and adaptive immune systems.  Odetiglucan is designed to form an immune complex in vivo via three receptors: Dectin-1, FcɣR, and CR3 and has been observed to drive anti-tumor immunity.

Unlike many other PRR agonists (cGAS-STING, TLR, etc.), Odetiglucan has been observed clinically to be generally well-tolerated and systemically administered due to its non-inflammatory, chemokine-centric innate immune activation.  As a result, we believe that Odetiglucan is not limited to intratumoral injection and has been observed not to be reliant on abscopal effect for systemic change.

We have observed that Odetiglucan drives anti-tumor immunity by reprogramming the immunosuppressive tumor microenvironment, enhancing antigen presentation, priming a de-novo T cell immune response, and inducing trained immunity, driving a memory